

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 6,812,344 B1
DATED : November 2, 2004
INVENTOR(S) : Anand et al.

Page 1 of 6

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Title page, Item [54] and Column 1, line 2.

Title, "DICARBOXIMIDOL)" should read -- DICARBOXIMIDO) --.

Title page,

Item [57], **ABSTRACT**,

Line 8, "prostratic" should read -- prostatic --.

Column 1,

Line 31, "prostrate" should read -- prostate --.

Column 2,

Line 62, "penyl" should read -- phenyl --.

Line 62, "Therapeuetica" should read -- Therapeutica --.

Column 3,

Line 12, "2-[3-4aryi-" should read -- 2-[3-(4-aryl- --.

Line 14, "pynolidinediones" should read -- pyrrolidinediones --.

Line 15, "of N4-aryl" should read -- of N-(N4-aryl --.

Line 15, "-piperozinyhnethyl)4-" should read -- -piperozinylmethyl)-4- --.

Line 17, "of N(N4-" should read -- of N-(N4- --.

Line 49, "piperazine" should read -- piperazin --.

Line 51, "antisehemic" should read -- antischemic --.

Line 57, "60 1D" should read -- 1D --.

Line 63, "requirement A for" should read -- requirement for --.

Column 4,

Line 1, "the" should read -- than --.

Line 26, "OC2H5" should read -- OC2H5 --.

Line 27, "C2H5" should read -- C2H5 --.

Line 57, "Z" R'1" should read -- Z', R1 -- (both).

Line 64, "piperazine" should read -- piperazin --.

Line 66, "(2-Methox phenyl)piper azin-1-yl]" should read -- (2-Methoxyphenyl) piperazin-1-yl] --.

Column 5,

Lines 1, 3, 5, 7, 9, 13, 15, 17, 19, 21, 25, 27, 29, 31 and 32, "piperazine" should read -- piperazin --.

Line 8, "5dioxopyrrolidin" should read -- 5-dioxopyrrolidin --.

Line 9, "4(2" should read -- 4-(2 --.

Line 10, "dioxoyrrolidin- 1-yl" should read -- dioxoyrrolidin-1-yl --.

Line 13, "-4(2" should read -- -4-(2 --.

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 6,812,344 B1
DATED : November 2, 2004
INVENTOR(S) : Anand et al.

Page 2 of 6

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 5 (cont'd),

Line 15, "[1-4]" should read -- [-4- --.
Line 15, "-Methoxyphenyl)" should read -- -Methoxyphenyl) --.
Line 15, "-2(2)" should read -- -2-(2 --.
Line 16, "5dioxopyrrolidin" should read -- 5-dioxopyrrolidin --.
Lines 17 and 19, "]-3(2)" should read --]-3-(2 --.
Lines 19 and 23, "-[4(4-" should read -- -[4-(4- --.
Line 20, "5dioxopyrrolidin" should read -- 5-dioxopyrrolidin --.
Line 20, "-1-ylopropane" should read -- -1-yl)propane --.
Line 23, "piperann-1-yl)" should read -- piperazin-1-yl --.
Line 26, "dioxopiperidia-1-yl)propant" should read -- dioxopiperidin-1-yl)propane --.
Line 27, "1-4-(3)" should read -- 1-[4-(3 --.
Line 32, "6dioxopiperidin" should read -- 6-dioxopiperidin --.
Line 33, "6-dioxopiperidin" should read -- 6-dioxopiperidin --.
Line 35, "piperazine-1-yl)" should read -- piperazin-1-yl --.
Line 37, "-[4(3,4-" should read -- -[4-(3,4- --.
Line 37, "piper-1-yl]-3(2)" should read -- piperazin-1-yl]-3-(2 --.

Column 6,

Line 1, "-[4(2-Pyrimidi)" should read -- -[4-(2-Pyrimidyl) --.
Line 1, "2,6dioxopiperidin-" should read -- 2,6-dioxopiperidin --.
Lines 1, 3, 5, 7 and 9, "piperazine" should read -- piperazin --.
Line 4, "6dioxopiperidia" should read -- 6-dioxopiperidin --.
Line 5, "1-[4(4)" should read -- 1-[4-(4- --.
Line 6, "6dioxopiperidin-1-yl)propine" should read -- 6-dioxopiperidin-1-yl)propane --.
Line 7, "]- (2,6-" should read --]-4-(2,6- --.
Line 8, "dioxopiperidin" should read -- dioxopiperidin --.
Lines 9 and 10, "[2-ioxo-3-phenyl-pyrolidin-1-yl]" should read -- [2,5-dioxo-3-phenyl-pyrolidin-1-yl] --.
Line 11, "(Phenyo)" should read -- "(Phenyl) --.
Line 11, "-3-2,5-" should read -- -3-[2,5- --.
Line 22, "for C) Schemes" should read -- for Schemes --.
Line 27, "R4" should read -- R₄ --.
Line 27, "n Z," should read -- n, Z, --.
Line 27, "Z', Q" should read -- Z', Q --.
Line 29, "(α, ω-" should read -- α, ω- --.
Line 30, "aryl piperazin-1-yl)" should read -- arylpiperazin-1-yl --.
Line 33, "1(4-" should read -- 1-(4- --.
Line 34, "odicarboximido" should read -- dicarboximido --.

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 6,812,344 B1
DATED : November 2, 2004
INVENTOR(S) : Anand et al.

Page 3 of 6

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 7,

Line 2, "Formula H" should read -- Formula II --.
Line 31, "ωdihaloalkanes" should read -- ω-dihaloalkanes --.
Line 31, "l(ω-" should read -- l-(ω --.
Line 40, "tetrabutylammonium" should read -- tetrabutylammonium --.

Column 8,

Line 30, "piperaiies" should read -- piperazines --.
Line 31, "synthesizd" should read -- synthesized --.
Lines 32 and 33, "V. 21, C) p. 1301" should read -- V. 21, p. 1301 --.
Line 34, "Aggarwat" should read -- Aggarwal --.
Line 38, "Pharmacological:" should read -- Pharmacological --.
Line 42, "aays" should read -- assays --.

Column 9,

Lines 1 and 2, "characterizton" should read -- characterization --.
Line 5, "in vitro" should read -- *in vitro* --.
Line 12, "manuals" should read -- mammals --.
Line 22, "parenterally. in" should read -- parenterally in --.
Line 23, "phanuceutcal" should read -- pharmaceutical --.
Line 24, "[4(" should read -- [4- --.
Line 25, "piperazine" should read -- piperazin -- (both occurrences).
Line 27, "]4-" should read --]-4- --.
Line 29, "6dioxopiperidin" should read -- 6-dioxopiperidin --.
Line 31, "Pharmaceutically" should read -- Pharmaceutically --.
Line 38, "bisruethylene salicylic" should read -- bismethylene salicylic --.
Line 47, "fimctional" should read -- functional --.
Line 48, "in vivo" should be -- *in vivo* --.
Line 59, "rcipients" should read -- excipients --.
Line 64, "compounds. of" should read -- compounds of --.

Column 10,

Lines 1, 44, 50 and 54, "piperazine" should read -- piperazin --.
Line 2, "-3[2" should read -- -3-[2 --.
Lines 2 and 31, "5dioxopyrroidin" should read -- 5-dioxopyrrolidin --.
Line 6, "moil" should read "mmol".
Line 6, "-fluorophenyl) -piperazine-1-yl]" should read -- -fluorophenyl)-piperazin-1-yl] --.
Lines 10, 14 and 23, "in vacuo" should read -- *in vacuo* --.
Line 13, "mnl" should read -- ml --.
Line 18, "-3-[4" should read -- -3-[4- --.
Line 18, "succiznic" should read -- succinic --.

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 6,812,344 B1
DATED : November 2, 2004
INVENTOR(S) : Anand et al.

Page 4 of 6

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 10 (cont'd),

Line 27, "flash ii silica" should read -- flash silica --.
Line 30, "3 Scheme- III" should read -- Scheme-III --.
Line 34, "N-direthylformamide" should read -- N-dimethylformamide --.
Line 43, "[4(4-" should read -- [4-(4- --.
Line 44, "-3 2,5" should read -- -3-(2,5 --.
Line 51, "propane in" should read -- propane --.
Line 53, "1b Scheme-I" should read -- Scheme-I --.
Line 58, "stirrig" should read -- stirring --.
Line 61, "(2X50)" should read -- (2X50 ml), --.
Line 64, "chloroforin" should read -- chloroform --.

Column 11,

Line 1, "1choloro" should read -- 1-chloro --.
Line 3, "rnmol" should read -- mmol --.
Line 5, "dirnethylformamide" should read -- dimethylformamide --.
Line 14, "dioxopyrrolidin" should read -- dioxopyrrolidin --.
Line 17, "tetrabutylammoniwn" should read -- tetrabutylammonium --.
Line 18, "methox phenyl" should read -- methoxyphenyl --.
Lines 18, 42 and 46, "piperazine" should read -- piperazin --.
Line 19, "[4,[" should read --]-3-[--.
Line 21, "1 chloro" should read -- 1-chloro --.
Line 21, "2,5dioxopyrrolidin" should read -- 2,5-dioxopyrrolidin --.
Line 23, "minol)" should read -- mmol) --.
Line 25, "nmol" should read -- mmol --.
Line 31, "[4(2-" should read -- [4-(2- --.
Line 32, "piperizine 1-yl]4" should read -- piperazin-1-yl]-4 --.
Line 32, "dioxopyrrolid" should read -- dioxopyrrolidin --.
Line 38, "Chloro4-" should read -- Chloro -4- --.
Line 38, "doxopyrrolidin" should read -- dioxopyrrolidin --.
Line 41, "tetrabutylaminonium" should read -- tetrabutylammonium --.
Line 42, "-14-" should read -- -[4- --.
Line 46, "smol)" should read -- mmol) --.
Line 46, "yl]-3-" should read -- yl]-3 --.
Line 48, "mmmol" should read -- mmol --.
Line 49, "aetone" should read -- acetone --.
Line 54, "tide" should read -- title --.
Line 60, "chloro3-2,6dioxopiperidin" should read -- chloro-3-(2,6-dioxopiperidin --.
Line 61, "1-methoxyphenyl)" should read -- 1-(2-methoxyphenyl) --.
Line 67, "tover" should read -- over --.

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 6,812,344 B1
DATED : November 2, 2004
INVENTOR(S) : Anand et al.

Page 5 of 6

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 12,

Line 3, "rnmethaol" should read -- methanol --.
Line 12, "[4(4-" should read -- [4-(4- --.
Lines 15, 17, 25, 27, 30, 32, 35, 37, 40, 43, 50, 53, 56, 60, 63 and 66, "piperazine" should read -- piperazin --.
Lines 15 and 16, "-342,5dioxopyrrolidin" should read -- -3-(2,5-dioxopyrrolidin --.
Line 18, "diopyrrolidin" should read -- dioxopyrrolidin --.
Line 20, "piperazine -1-yl]-3(2,5dioxopyrrolidin" should read -- piperazin-1-yl]-3-(2,5-dioxopyrrolidin --.
Line 22, "(3Chloropheuy)" should read -- (3-Chlorophenyl) --.
Lines 22 and 23, "1-3) 2,5dioxopyrrolidin" should read -- -3-(2,5-dioxopyrrolidin --.
Line 23, "hydrochlond" should read -- hydrochloride --.
Line 27, "[4-3,4-" should read -- [4-(3,4- --.
Lines 27 and 28, "-3(2,5dioxopyrrolidin" should read -- -3-(2,5-dioxopyrrolidin --.
Line 30, "(2,5dioxopyrrolidin" should read -- (2,5-dioxopyrrolidin --.
Line 32, "1-[4(2-" should read -- 1-[4-(2 --.
Line 33, "m.p. 218-220° C." should read -- m.p. 219-220° C. --.
Lines 35 and 36, "dioxpyrrolidin" should read -- dioxopyrrolidin --.
Line 37, "[4-3-Methoyphenyl" should read -- [4-(3-Methoxyphenyl --.
Line 37, "-3(2,5 -dioxopyrroldin" should read -- -3-(2,5-dioxopyrrolidin --.
Line 43, "-3(2,6-" should read -- -3-(2,6- --.
Line 44, "205-207° C" should read -- 206-210° C --.
Line 46, "1-[(4-4-" should read -- 1-[4-(4- --.
Line 46, "piperazn" should read -- piperazin --.
Line 48, "(4Chlorophenyl)" should read -- (4-Chlorophenyl) --.
Line 56, "(2Methylphenyl)" should read -- (2-Methylphenyl) --.
Line 56, "-3(2,6-dioxopiperidin-" should read -- -3-(2,6-dioxopiperidin- --.
Line 58, "(Pyrdyl)piperazin-1-yl-" should read -- (2-Pyridyl)piperazin-1-yl)- --.
Line 58, "dioxopiperidin" should read -- dioxopiperidin --.
Line 60, "-3 -" should read -- -3- --.
Line 61, "dioxopiperidin -1" should read -- dioxopiperidin-1 --.
Line 64, "dioxopiperidinl" should read -- dioxopiperidin --.
Line 64, "hydro-chloride" should read -- hydrochloride --.

Column 13,

Lines 1, 4, 7 and 10, "piperazine" should read -- piperazin --.
Line 4, "1-[(4-4-" should read -- 1-[4-(4- --.
Line 7, "J4-(" should read --]4-(--.
Line 8, "6dioxopiperidin" should read -- 6-dioxopiperidin --.
Line 19, "assays. (RBA's)" should read -- assays (RBA's) --.
Line 22, "α_{1A}" should read -- α_{1A} --.

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 6,812,344 B1
DATED : November 2, 2004
INVENTOR(S) : Anand et al.

Page 6 of 6

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 14,

Line 2, "against" should read -- agonist --.
Line 5, "vistar" should read -- wistar --.
Line 7, "CaCl₂," should read -- CaCl₂ 2.5; --.
Line 30, "Muscannic" should read -- Muscarinic --.
Line 66, "β_B" should read -- β₁ --.

Column 15,


Line 21, "Antih Pertensive" should read -- Antihypertensive --.
Line 29, "g/kg" should read -- g/kg --.
Line 30, "Statharn" should read -- Statham --.
Line 62, "Normotensive" should read -- Normotensive --.

Column 16,

Line 60, "digitalpressure" should read -- digital pressure --.

Signed and Sealed this

Fourth Day of October, 2005

A handwritten signature in black ink, appearing to read "Jon W. Dudas". The signature is stylized with a large, looped initial "J" and a distinct "D" at the end.

JON W. DUDAS
Director of the United States Patent and Trademark Office